[Tc]Tc-HYNIC-RM2: A potential SPECT probe targeting GRPR expression in prostate cancers.

INTRODUCTION

Elevated density of gastrin releasing peptide receptors (GRPR) in prostate cancer has led to exploration of several radiolabeled peptides for imaging and staging of the disease. The GRPR antagonist peptide RM2 has been successfully conjugated with several chelators and radiolabeled with gallium-68. The goal of this study was to synthesize a Tc-labeled probe and investigate its potential for SPECT imaging of prostate cancer. Towards this HYNIC-RM2 peptide conjugate was synthesized, radiolabeled with Tc and evaluated in GRPR-positive PC3 tumor xenografts.

METHODS

HYNIC-RM2 was manually synthesized by standard Fmoc solid phase strategy and radiolabeled with Tc. In vitro cell studies were performed in GRPR-positive human prostate carcinoma (PC3) cells. Metabolic stability studies of [Tc]Tc-HYNIC-RM2 were performed in normal mice in the presence as well as absence of neutral endopeptidase (NEP) inhibitor, phosphoramidon (PA). Biodistribution and imaging studies of [Tc]Tc-HYNIC-RM2 were performed in SCID mice bearing PC3-xenograft.

RESULTS

[Tc]Tc-HYNIC-RM2 exhibited high binding affinity in low nanomolar range (K = 1.83 ± 0.31 nM). Metabolic stability studies in mice indicated that in the absence of PA, radiolabeled peptide was about 65 % intact in the blood at 15 min p.i., whereas proportion of intact radiolabeled peptide was enhanced to 90 % on co-administration of PA. Biodistribution studies in PC3 tumor bearing mice demonstrated high tumor uptake (8.02 ± 0.9%ID/g and 6.13 ± 0.44%ID/g at 1 h and 3 h p.i.). Co-administration of PA with the radiolabeled peptide resulted in further enhancement of tumor uptake (14.24 ± 0.76 % ID/g and 11.71 ± 0.59%ID/g at 1 h and 3 h p.i.). SPECT/CT images of [Tc]Tc-HYNIC-RM2 could clearly visualize the tumor. Significant (p < 0.001) reduction in the tumor uptake with a co-injected blocking dose of unlabeled peptide ascertained the GRPR specificity of [Tc]Tc-HYNIC-RM2.

CONCLUSION

Encouraging results obtained in biodistribution and imaging studies indicate the potential of [Tc]Tc-HYNIC-RM2 for further exploration as GRPR targeting agent.